Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.
作者信息
Cohen Stuart H, Louie Thomas J, Sims Matthew, Wang Elaine E L, Memisoglu Asli, McGovern Barbara H, von Moltke Lisa
机构信息
University of California Davis Health, Sacramento.
Cumming School of Medicine University of Calgary, Calgary, Alberta, Canada.
出版信息
JAMA. 2022 Nov 22;328(20):2062-2064. doi: 10.1001/jama.2022.16476.
Abstract
摘要
相似文献
1
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.在一项随机临床试验中，对微生物组疗法SER-109针对复发性艰难梭菌感染进行长达24周的延长随访。
JAMA. 2022 Nov 22;328(20):2062-2064. doi: 10.1001/jama.2022.16476.
2
SER-109, an Oral Microbiome Therapy for Recurrent Infection.SER-109，一种用于复发性感染的口腔微生物组疗法。
N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516.
3
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.SER-109，一种用于减少艰难梭菌感染后复发的研究性微生物组药物：来自 2 期试验的经验教训。
Clin Infect Dis. 2021 Jun 15;72(12):2132-2140. doi: 10.1093/cid/ciaa387.
4
[SER-109: oral microbiome therapy for recurrent Clostridioides difficile infections : SER-109 versus Placebo in the Treatment of Adults with Recurrent Clostridium Difficile Infection (ECOSPOR III)].[SER-109：用于复发性艰难梭菌感染的口腔微生物群疗法：SER-109与安慰剂治疗复发性艰难梭菌感染成人患者的对比研究（ECOSPOR III）]
Inn Med (Heidelb). 2022 Jul;63(7):805-807. doi: 10.1007/s00108-022-01346-4. Epub 2022 May 17.
5
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.RBX2660 治疗后艰难梭菌感染复发和微生物组恢复的持久减少：一项开放标签 2 期临床试验的结果。
BMC Infect Dis. 2022 Mar 12;22(1):245. doi: 10.1186/s12879-022-07256-y.
6
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.在复发性艰难梭菌感染的成人中作为研究用微生物组治疗药物的 SER-109 的安全性和耐受性：一项 3 期、开放标签、单臂试验。
JAMA Netw Open. 2023 Feb 1;6(2):e2255758. doi: 10.1001/jamanetworkopen.2022.55758.
7
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.复发性艰难梭菌感染：当前的临床管理及基于微生物群的治疗方法
BioDrugs. 2023 Nov;37(6):757-773. doi: 10.1007/s40259-023-00617-2. Epub 2023 Jul 26.
8
RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.RBX7455，一种非冷冻、口服的研究性活体生物治疗药物，在复发性艰难梭菌感染的 1 期研究中安全、有效，并能改变患者的微生物组。
Clin Infect Dis. 2021 Oct 5;73(7):e1613-e1620. doi: 10.1093/cid/ciaa1430.
9
Unexpected Results From a Phase 2 Trial of a Microbiome Therapeutic for Clostridioides difficile Infection: Lessons for the Future.艰难梭菌感染微生物组疗法2期试验的意外结果：对未来的启示
Clin Infect Dis. 2021 Jun 15;72(12):2141-2143. doi: 10.1093/cid/ciaa476. Epub 2020 Apr 24.
10
Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection.微生物组疗法SER-109用于复发性艰难梭菌感染的长期随访
JAMA. 2023 Mar 28;329(12):1032-1033. doi: 10.1001/jama.2023.0497.
引用本文的文献
1
Intestinal Microbiota and Fecal Transplantation in Patients with Inflammatory Bowel Disease and : An Updated Literature Review.炎症性肠病患者的肠道微生物群与粪便移植：文献综述更新
J Clin Med. 2025 Jul 25;14(15):5260. doi: 10.3390/jcm14155260.
2
Patient Satisfaction Scale Following a Laxative for Antibiotic Washout Prior to Oral Microbiome Therapy.口服微生物组治疗前用于抗生素清除的泻药后的患者满意度量表
Adv Ther. 2025 Jan;42(1):490-499. doi: 10.1007/s12325-024-03065-8. Epub 2024 Nov 28.
3
Microbiome-based therapeutics for Parkinson's disease.基于微生物组的帕金森病治疗方法。
Neurotherapeutics. 2024 Oct;21(6):e00462. doi: 10.1016/j.neurot.2024.e00462. Epub 2024 Oct 11.
4
Systematic review of the orally administered microbiome therapeutic, fecal microbiota spores, live-brpk, to prevent recurrence of infection in adults.口服微生物群疗法——粪便微生物群孢子（活芽孢）预防成人感染复发的系统评价
SAGE Open Med. 2024 Oct 9;12:20503121241274192. doi: 10.1177/20503121241274192. eCollection 2024.
5
A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation.系统理解人类健康和疾病中微生物组的框架：从基础原理到临床转化。
Signal Transduct Target Ther. 2024 Sep 23;9(1):237. doi: 10.1038/s41392-024-01946-6.
6
Therapeutics involved in managing initial and recurrent infection: An updated literature review.治疗初发和复发性感染的疗法：文献综述更新
World J Gastrointest Pharmacol Ther. 2024 Sep 5;15(5):95467. doi: 10.4292/wjgpt.v15.i5.95467.
7
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.一种用于复发性艰难梭菌感染的微生物组疗法3期试验的综合安全性和有效性分析。
Infect Dis Ther. 2024 Oct;13(10):2105-2121. doi: 10.1007/s40121-024-01007-z. Epub 2024 Jun 28.
8
Efficacy of Fecal Microbiota (REBYOTA) in Recurrent Clostridium difficile Infections: A Systematic Review and Meta-Analysis.粪便微生物群（REBYOTA）在复发性艰难梭菌感染中的疗效：一项系统评价和荟萃分析
Cureus. 2024 Apr 23;16(4):e58862. doi: 10.7759/cureus.58862. eCollection 2024 Apr.
9
SER-109 (VOWST): A Review in the Prevention of Recurrent Clostridioides difficile Infection.SER-109（VOWST）：预防复发性艰难梭菌感染的研究综述。
Drugs. 2024 Mar;84(3):329-336. doi: 10.1007/s40265-024-02006-7. Epub 2024 Mar 5.
10
Microbiota-Based Live Biotherapeutic Products for Infection- The Devil is in the Details.用于感染治疗的基于微生物群的活体生物治疗产品——细节决定成败。
Infect Drug Resist. 2024 Feb 15;17:623-639. doi: 10.2147/IDR.S419243. eCollection 2024.
Zotero 插件